Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

The lectin-like domain of thrombomodulin hampers host defence in pneumococcal pneumonia

Marcel Schouten, J. Daan de Boer, Cornelis van ’t Veer, Joris J.T.H. Roelofs, Joost C.M. Meijers, Marcel Levi, Edward M. Conway, Tom van der Poll
European Respiratory Journal 2013 41: 935-942; DOI: 10.1183/09031936.00015212
Marcel Schouten
*Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center, University of Amsterdam, Amsterdam
#Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: m.schouten@amc.uva.nl
J. Daan de Boer
*Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center, University of Amsterdam, Amsterdam
#Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cornelis van ’t Veer
*Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center, University of Amsterdam, Amsterdam
#Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joris J.T.H. Roelofs
¶Dept of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joost C.M. Meijers
+Dept of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcel Levi
§Dept of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward M. Conway
fCentre for Blood Research, Life Sciences Institute, Division of Hematology-Oncology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom van der Poll
*Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center, University of Amsterdam, Amsterdam
#Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam
§Dept of Internal Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The lectin-like domain of thrombomodulin (TM) plays an important regulatory role in sterile inflammatory conditions, but its role in severe Gram-positive infectious disease is unknown. Streptococcus pneumoniae is the most common cause of community-acquired pneumonia. The aim of this study was to determine the role of the lectin-like domain of TM in murine pneumococcal pneumonia.

Wild-type (WT) mice and mice lacking the lectin-like domain of TM (TMLeD/LeD) were infected intranasally with viable S. pneumoniae and either observed in a survival study or euthanised 6, 24 or 48 h after infection.

TMLeD/LeD mice had a markedly better survival in pneumococcal pneumonia when compared with WT mice. At 48 h post-infection with S. pneumoniae, TMLeD/LeD mice had lower bacterial loads in blood and liver, and exhibited less pulmonary inflammation, as shown by having less lung histopathology, less neutrophil influx and lower cytokine and chemokine levels. Plasma levels of pro-inflammatory cytokines were also reduced in TMLeD/LeD mice after exposure to the infection.

Deletion of the lectin-like domain of TM improves the host defence in pneumococcal pneumonia. The lectin-like domain of TM may have a differential role in response to Gram-positive or Gram-negative bacteria.

  • Coagulation
  • inflammation
  • sepsis
  • Streptococcus pneumoniae

The leading cause of community-acquired pneumonia is Streptococcus pneumoniae [1]. Annually, ∼570 000 cases of pneumococcal pneumonia occur in the USA, accounting for ∼175 000 hospitalisations [2]. When associated with sepsis, mortality rates of pneumococcal pneumonia can exceed 20% [3]. Worldwide, S. pneumoniae is responsible for an estimated 10 million deaths per year [4]. Together with the increasing incidence of antibiotic resistance to this pathogen [1], there is an urgent need to expand our knowledge of host defence mechanisms that influence the outcome of pneumococcal pneumonia and sepsis.

Thrombomodulin (TM) CD141 is a transmembrane, multidomain glycoprotein receptor that is expressed predominantly on vascular endothelial cells, but also on monocytes, neutrophils, osteoblasts, synovial cells and dendritic cells [5–7]. TM exhibits several distinct properties in coagulation, fibrinolysis, innate immunity and inflammation that are based largely on its distinct structural domains. The central domain of TM is comprised of six epidermal growth factor (EGF)-like repeats, three of which provide critical cofactor activity for the thrombin-mediated generation of activated protein C (APC) and of activated thrombin-activatable fibrinolysis inhibitor (TAFIa). Protein C activation by thrombin–TM is further augmented by the endothelial protein C receptor [5–7]. APC suppresses further generation of thrombin by cleaving and inactivating coagulation cofactors Va and VIIIa. APC also has profound anti-inflammatory properties [8–10]. The plasma carboxypeptidase B, TAFIa, inhibits fibrinolysis by modifying fibrinogen, rendering the fibrin resistant to plasminogen binding, and limiting plasmin generation [11]. TAFIa also inactivates the complement fragments and anaphylatoxins C3a and C5a, thereby dampening the innate immune response [12]. In addition to its pivotal role in activating protein C and TAFI [8, 11], TM also has direct anti-inflammatory properties [5–7] that are mediated at least in part by its N-terminal C-type lectin-like domain. This structure interferes with neutrophil adhesion, complement activation and cytokine generation [13–15], and mice lacking the lectin-like domain of TM (TMLeD/LeD mice) exhibit increased sensitivity to tissue injury in models of endotoxaemia, lung and myocardial ischaemia-reperfusion and inflammatory arthritis [13–15].

Although alterations in regulation of the coagulation system have been studied extensively in pneumonia and sepsis [8], there is limited knowledge of the role of TM in the host response to bacterial infection. As TM is highly expressed in the lung, particularly in the alveolar capillary endothelial cells [16, 17], we have been evaluating its participation in the response to respiratory tract infections. Mice with a point mutation in the gene encoding TM, which significantly reduces its capacity to generate APC and lowers TM antigen levels, surprisingly did not exhibit alterations in the pulmonary response to endotoxin or to respiratory pathogens, including S. pneumoniae [18]. Using TMLeD/LeD mice and their counterpart wild-type (WT) mice, we sought to determine the in vivo role of the lectin-like domain of TM in the response to pneumococcal pneumonia.

MATERIALS AND METHODS

Animals

TMLeD/LeD mice were generated as described [13] and backcrossed eight times to a C57BL/6 genetic background. TMLeD/LeD mice express normal antigenic levels of TM, and activation of protein C is intact and unaffected by the deletion of the lectin-like domain [13]. C57BL/6 WT mice were purchased from Charles River (Maastricht, the Netherlands). All experiments were approved by the Institutional Animal Care and Use Committee of the University of Amsterdam (Amsterdam, the Netherlands).

Experimental infection and sampling

Pneumonia was induced by intranasal inoculation with ∼5×104 CFU of S. pneumoniae serotype 3 (ATCC 6303; American Type Culture Collection, Rockville, MD, USA) as described [18, 19]. Mice were observed for 1 week (n=14 per group), after which survivors were killed or were euthanised at predefined time-points (n=8 per group per time-point). Citrated plasma was prepared from blood drawn from the inferior vena cava. Organ homogenates were prepared as described [18, 19]. In brief, the left lung and approximately half of the spleen and liver were harvested and homogenised at 4°C in four volumes of sterile saline using a tissue homogeniser (Biospect Products, Bartlesville, UK). Bacterial outgrowth in organ homogenates was determined as described [18, 19]. For further measurements in lung tissue, lung homogenates were diluted 1:2 with lysis buffer (300 mM NaCl, 30 mM Tris, 2 mM MgCl2, 2 mM CaCl2, 1% (volume/volume) Triton X-100, pH 7.4) with protease inhibitor mix added (4-(2-aminoethyl)benzenesulfonylfluoride (AEBSF)), EDTA-NA2, pepstatin and leupeptin, all purchased from MP Biomedical (Eindhoven, the Netherlands) and incubated for 30 min on ice, followed by centrifugation at 680×g for 10 min. Supernatants were stored at -20°C until analysis.

In a separate series of experiments, the trachea was exposed and canulated with a sterile 22-gauge Abbocath-T catheter (Abott, Sligo, Ireland) after which bronchoalveolar lavage (BAL) was performed by instilling and retrieving two 0.5 mL aliquots of saline (n=8 per group per time-point). Cell counts were determined for each BAL fluid (BALF) sample in a haemocytometer (Beckman Coulter, Fullerton, CA, USA). Differential cell counts were performed on cytospins stained with Giemsa stain (Diff-Quick; Dade Behring AG, Düdingen, Switzerland).

Histology and immunohistochemistry

The right lung was fixed in 10% formalin/PBS at room temperature for 24 h and subsequently embedded in paraffin; 5-μm thick sections were cut. Granulocyte staining was performed using fluorescein isothiocyanate–labelled anti-mouse-Ly-6G monoclonal antibody (Pharmingen, San Diego, CA, USA) as described [20]. Ly-6G stained slides were photographed with a microscope equipped with a digital camera (Leica CTR500; Leica Microsystems, Wetzlar, Germany). 10 random pictures were taken per slide. Stained areas were analysed with Image Pro Plus (Media Cybernetics, Bethesda, MD, USA) and expressed as a percentage of the total surface area. Slides were also stained with haematoxylin and eosin and analysed by a pathologist who was blinded to the identity of the different groups. To score lung inflammation and damage, the entire lung section was analysed with respect to the following parameters: bronchitis, interstitial inflammation, oedema, endothelialitis, pleuritis and thrombus formation. Each parameter was graded on a scale of 0–4 (0: absent; 1: mild; 2: moderate; 3: severe; and 4: very severe). The total histopathological score was expressed as the sum of the scores for the different parameters.

Assays

Myeloperoxidase (MPO) (HyCult Biotechnology, Uden, the Netherlands) was measured by ELISA. Tumour necrosis factor (TNF)-α, interleukin (IL)-6, monocyte chemoattractant protein (MCP)-1, IL-12p70, interferon (IFN)-γ and IL-10 were measured by cytometric bead array multiplex assay (BD Biosciences, San Jose, CA, USA). Keratinocyte-derived chemokine (KC) and macrophage inflammatory protein (MIP)-2 were measured by ELISA (R&D Systems, Minneapolis, MN, USA). Thrombin–antithrombin complexes (TATc) were measured by ELISA (Siemens Healthcare Diagnostics, Marburg, Germany).

Statistical analysis

Data are expressed either as box-and-whisker plots depicting the smallest observation, lower quartile, median, upper quartile and largest observation, as medians with interquartile ranges or as Kaplan–Meier plots. Differences between groups were determined with Mann–Whitney U-test or log rank test where appropriate. Analyses were performed using GraphPad Prism version 4.0 (GraphPad Software, San Diego, CA, USA). p-values of <0.05 were considered statistically significant.

RESULTS

TMLeD/LeD mice exhibit a survival advantage after pneumococcal infection

To determine whether the lectin-like domain of TM alters survival in response to lethal doses of S. pneumoniae, TMLeD/LeD and WT mice were inoculated intranasally with the bacteria and monitored for 1 week (fig. 1). TMLeD/LeD mice were significantly protected from the lethal infection as compared with WT mice (p<0.05), and started dying later than WT mice. Five out of 14 TMLeD/LeD mice were alive at the end of the study, whereas only one out of the 14 WT mice survived.

Figure 1–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1–

Loss of the lectin-like domain of thrombomodulin (TMLeD/LeD) reduces mortality in murine pneumococcal pneumonia. Survival of wild-type (WT) mice and mice lacking the TMLeD/LeD after intranasal infection with 5×104 Streptococcus pneumoniae CFU (14 mice per group). *: p<0.05, statistical significance as compared with WT using log rank test.

TMLeD/LeD mice show diminished dissemination of the infection

To determine whether the difference in survival between TMLeD/LeD and WT mice could be attributed to a difference in antibacterial defence, we measured bacterial outgrowth 6, 24 and 48 h post-infection in lungs, blood and distant organs (spleen and liver) (fig. 2). At 6 h, TMLeD/LeD mice had slightly lower bacterial loads in their lungs than WT mice (p<0.05) (fig. 2a). However, at later time-points, there were no detectable differences in lung bacterial burdens in the different genotype mice (fig. 2a). Whereas cultures in blood and distant organs were almost invariably negative during the first 24 h after infection (fig. 2b–d), at 48 h the majority of mice displayed systemic infection. Notably, at this time-point, TMLeD/LeD mice had significantly lower bacterial counts in blood (fig. 2b) and liver (fig. 2d) as compared with WT mice (both p<0.05), whereas pneumococcal loads in spleen (fig. 2c) were not significantly different between groups.

Figure 2–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2–

Bacterial outgrowth in blood and liver is lower in mice lacking the lectin-like domain of thrombomodulin (TMLeD/LeD) as compared with wild-type (WT) mice after pneumococcal infection. Bacterial outgrowth in a) lung, b) blood, c) spleen and d) liver 6, 24, and 48 h after induction of pneumonia by intranasal inoculation with 5×104 Streptococcus pneumoniae CFU in WT and TMLeD/LeD mice. Data are expressed as box-and-whisker plots depicting the smallest observation, lower quartile, median, upper quartile and largest observation (eight mice per group). BD: below detection. *: p<0.05, statistical significance as compared with WT using Mann–Whitney U-test.

Lungs of TMLeD/LeD mice are relatively resistant to pro-inflammatory effects of S. pneumoniae

Pneumococcal pneumonia was associated with pulmonary inflammation and damage as evidenced by influx of neutrophils into the lungs and the occurrence of bronchitis, interstitial inflammation, oedema and endothelialitis. The absence of the lectin-like domain of TM in mice results in enhanced neutrophil accumulation in the lungs subsequent to endotoxin inhalation [13]. To assess the role of the lectin-like domain of TM on neutrophil influx into the pulmonary compartment in response to pneumococcal pneumonia, we performed Ly-6G staining on lung sections and measured MPO levels in lung homogenates at 24 and 48 h post-infection. While there were no differences at 24 h (data not shown), Ly-6G positivity at 48 h was significantly lower in the lungs of TMLeD/LeD mice than of WT mice, indicating reduced neutrophil accumulation (fig. 3a–c). MPO levels were also significantly lower in lung homogenates of TMLeD/LeD mice at 48 h (fig. 3d). In line with these findings, mean histopathological scores of lung sections at the same time-point were lower in TMLeD/LeD mice (fig. 4). To investigate whether differences in lung tissue neutrophil influx resulted in differences in cell influx in the bronchoalveolar compartment, we determined total cell counts, neutrophil numbers and MPO in BALF at 6, 24 and 48 h after induction of pneumococcal pneumonia. There were no differences in total cell counts and neutrophil numbers between TMLeD/LeD and WT mice at any of the time-points studied (table 1). Moreover, BALF MPO levels were not different (not shown).

Figure 3–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3–

Lung neutrophil influx and myeloperoxidase (MPO) levels are lower in mice lacking the lectin-like domain of thrombomodulin (TMLeD/LeD) as compared with wild-type (WT) mice after pneumococcal infection. Representative slides of lung fluorescein isothyocyanate anti-mouse Ly-6G staining (brown) 48 h after induction of pneumonia by intranasal inoculation with 5×104 Streptococcus pneumoniae CFU in a) WT mice and b) TMLeD/LeD mice. Scale bars=100 μm. c) Quantitation of pulmonary Ly-6G 48 h after induction of pneumococcal pneumonia in WT mice and TMLeD/LeD mice. d) Lung levels of MPO 48 h post-infection with pneumococcal pneumonia in WT mice and TMLeD/LeD mice. Data are expressed as box-and-whisker plots depicting the smallest observation, lower quartile, median, upper quartile and largest observation (eight mice per group). **: p<0.01, statistical significance as compared with WT using Mann–Whitney U-test.

Figure 4–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4–

Total histopathology scores are lower in mice lacking the lectin-like domain of thrombomodulin (TMLeD/LeD) as compared with wild-type (WT) mice after pneumococcal infection. Representative slides of lung haematoxylin and eosin stainings 48 h after induction of pneumonia by intranasal inoculation with 5×104 Streptococcus pneumoniae CFU in a) WT mice and b) TMLeD/LeD mice. Scale bars=100 μm. c) Total pathology scores 48 h post-infection with pneumococcal pneumonia in WT mice and TMLeD/LeD mice. Data are expressed as box-and-whisker plots depicting the smallest observation, lower quartile, median, upper quartile and largest observation (eight mice per group). *: p<0.05, statistical significance as compared with WT using Mann-Whitney U-test.

View this table:
  • View inline
  • View popup
Table 1 Cell counts and differentials in bronchoalveolar lavage fluid in wild-type (WT) mice and mice lacking the lectin-like domain of thrombomodulin (TMLeD/LeD) 6, 24 and 48 h post-infection with pneumococcal pneumonia

We next quantified the levels of several chemokines and cytokines in lung homogenates at 6, 24 and 48 h post-infection (table 2). At 6 and 24 h, no differences in lung chemokines and cytokines were detected between the groups. However, at 48 h, lung homogenates from TMLeD/LeD mice had significantly lower levels of the chemokines KC and MIP-2 (p<0.05 and p<0.01 respectively), and reduced levels of TNF-α (p<0.001), IL-6, IL-10, IFN-γ and MCP-1 (p<0.05) (table 2).

View this table:
  • View inline
  • View popup
Table 2 Pulmonary cytokine and chemokine levels in wild-type (WT) mice and mice lacking the lectin-like domain of thrombomodulin (TMLeD/LeD) at 6, 24 and 48 h post-infection with pneumococcal pneumonia

Reduced plasma cytokine levels in TMLeD/LeD mice after S. pneumoniae infection

To further investigate the role of the lectin-like domain of TM in response to pneumococcal pneumonia we measured inflammatory markers in plasma. The differential inflammatory response between TMLeD/LeD mice and WT mice was already evident in plasma at 24 h post-infection, at which point levels of TNF-α, IL-6 and MCP-1 were significantly lower in TMLeD/LeD mice than in WT mice (table 3), a difference that was sustained until 48 h. Plasma levels of IL-10, IL-12 and IFN-γ were below the detection limit of the assays (not shown).

View this table:
  • View inline
  • View popup
Table 3 Plasma cytokine and chemokine levels in wild-type (WT) mice and mice lacking the lectin-like domain of thrombomodulin (TMLeD/LeD) 6, 24 and 48 h post-infection with pneumococcal pneumonia

TMLeD/LeD mice exhibit a dampened coagulation response to S. pneumoniae

We also evaluated whether the lectin-like domain of TM modified pneumococcal pneumonia-induced changes in coagulation activation by measuring TATc levels in lung homogenates and plasma. No differences in TATc levels were noted either at 6 and 24 h post-infection in plasma or in lung homogenates. However, at 48 h, when plasma TATc levels remained similar in both groups of mice (data not shown), TATc levels were significantly lower in lung tissue from TMLeD/LeD mice as compared with WT mice (p<0.05) (fig. 5).

Figure 5–
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5–

Activation of coagulation is reduced in the lung tissue of mice lacking the lectin-like domain of thrombomodulin (TMLeD/LeD) as compared with wild-type (WT) mice after pneumococcal pneumonia. Lung homogenate levels of thrombin-antithrombin complexes (TATc) 6, 24 and 48 h post-infection with 5×104 Streptococcus pneumoniae CFU in WT and TMLeD/LeD mice. Data are expressed as box-and-whisker plots depicting the smallest observation, lower quartile, median, upper quartile and largest observation (eight mice per group at each time-point). *: p<0.05, statistical significance as compared with WT using Mann–Whitney U-test.

DISCUSSION

Coagulation and inflammation are highly integrated and interactive participants in the immediate host response to infection. TM occupies a central role in the regulation of coagulation and inflammation, with responsibility for its specific functions relying on the integrity of its distinct structural domains. Thus, the EGF-like repeats provide cofactor activity for thrombin-mediated activation of protein C and TAFI, resulting in dampening of coagulation, fibrinolysis and complement, while the N-terminal lectin-like domain exhibits a number of anti-inflammatory properties [5–7]. Using mouse models to study the host response to bacterial pneumonia, we have previously investigated the role of the EGF-like repeat of TM, which is responsible for protein C activation. TMPro/Pro mice, which have moderately diminished levels of TM antigen and a dramatic reduction in its capacity to support thrombin-mediated activation of protein C, did not exhibit TM-dependent changes in the pro-coagulant or inflammatory response to bacterial pneumonia as compared with WT mice [18]. Here, we similarly studied the role of the lectin-like domain of TM in a mouse model of community-acquired pneumonia caused by S. pneumoniae. This domain of TM does not participate in the generation of APC. In contrast to sterile inflammation models, in which loss of the lectin-like domain of TM renders mice more sensitive to lung and myocardial ischaemia-reperfusion injury, inflammatory arthritis and endotoxaemia [13–15], loss of the lectin-like domain of TM appears to protect the host in response to pneumococcal pneumonia, as reflected by improved survival, reduced bacterial growth and dissemination, and attenuated inflammatory and pro-coagulant response in TMLeD/LeD mice as compared with WT mice.

This is the first report in which viable Gram-positive bacteria were used to evaluate the in vivo role of the lectin-like domain of TM. In our study, pneumococcal loads were transiently lower in the lungs of TMLeD/LeD mice 6 h post-infection. This difference could not be attributed to altered inflammatory cell numbers, as BALF total cell counts and neutrophil numbers were not different between WT and TMLeD/LeD mice at this early time-point after infection. Notably, noninfected TMLeD/LeD mice display a clearly enhanced neutrophil accumulation in the lung interstitium in peribronchial locations [13], which is expected to facilitate the immediate antibacterial response upon infection of the lower airways [21]. However, the difference became more prominent at 48 h post-infection, when bacterial loads in the blood and liver were found to be markedly lower in TMLeD/LeD than in WT mice. These data suggest that killing of S. pneumoniae at the lung–blood interface, i.e. at the endothelial cell layer or in the systemic compartment itself, is enhanced in the absence of the lectin-like domain of TM. It is possible that this may be due to excess complement activation at that site due to loss of the lectin-like domain of TM that otherwise downregulates complement activation [22]. Indeed, TMLeD/LeD mice have lower basal plasma C3 levels and a reduced CH50 (the amount of serum that causes 50% haemolysis of antibody-sensitised sheep erythrocytes), both of which are indicative of excess complement activation [15]. Considering the important role that complement activation plays in host defence against pneumococci in vivo [23], it is conceivable that the protective phenotype of TMLeD/LeD mice is at least in part explained by increased clearance of pneumococci from the bloodstream via augmented activation of the complement system.

In our study, TMLeD/LeD mice displayed less evidence of local and systemic inflammation in response to S. pneumoniae infection. This was reflected by lower plasma levels of TNF-α, IL-6 and MCP-1, less histological evidence of lung damage, lower levels of cytokines and chemokines in lung homogenates, fewer neutrophils in the infected lungs, reduced secondary activation of coagulation as measured by TATc, and finally by relative resistance to lethal doses of the bacteria. Although appearing to be contradictory to previous reports in which TMLeD/LeD mice exhibited a heightened inflammatory response, those studies were performed with endotoxin or nonbacterial stresses, rather than with live Gram-positive bacteria [13]. Indeed, the current findings suggest that TM via its lectin-like domain may mediate a differential host response to Gram-negative versus Gram-positive bacteria. The lectin-like domain of TM binds to the carbohydrate Lewis Y antigen of Gram-negative bacteria and induces agglutination and opsonisation of Gram-negative organisms, including Escherichia coli and Klebsiella pneumoniae, enhancing their phagocytosis by macrophages [24]. By interacting with the Lewis Y antigen, the lectin-like domain of TM may interfere with lipopolysaccharide binding to CD14, its cognate receptor, thereby dampening downstream pro-inflammatory signal pathways and the release of pro-inflammatory cytokines, and inducible nitric oxide synthase expression. Indeed, a recombinant soluble form of the lectin-like domain of TM reduced Klebsiella-induced inflammatory responses and lethality [24]. Without invoking other mechanisms, this beneficial response would not necessarily be expected in our Gram-positive pneumonia model, as endotoxin is not involved. The clinical relevance of this finding is important to recognise, as soluble thrombomodulin is being studied for use in the clinic [25] and identifying the appropriate application is critical to ensure optimal benefit. Also, whereas in nonbacterial stress models, anti-inflammatory responses tend to ameliorate damage, in live bacterial models, a substantial amount of inflammatory response is necessary to kill the bacteria; interfering with bacterial killing by reducing the inflammatory response can enhance bacterial outgrowth, in turn resulting in an adverse outcome.

Our study has limitations. As elaborated above, we studied a single pathogen in a single infection model. It is unclear if results from our study would be comparable to those in other models and/or using other bacteria. Also, it is possible that genetic knock-down of TMLeD/LeD has induced unknown compensatory changes in mice during growth and development. In this regard, it would be interesting to study the effect of interfering with the function of the TMLeD/LeD domain as opposed to knocking down TMLeD/LeD, for example, by using blocking antibodies.

In conclusion, we show that deletion of the lectin-like domain of TM in mice results in improved host defence against pneumococcal pneumonia, a common cause of serious community-acquired infection. Additional studies are necessary to obtain further insight into the possible differential role of the lectin-like TM domain in Gram-positive versus Gram-negative infections, as this will determine how to best design targeted therapies to either enhance the function or interfere with the function of this interesting endothelial C-type lectin-like structure, thereby gaining maximal benefit in different clinical situations.

Acknowledgments

The authors thank the following people, all working at the Center for Experimental and Molecular Medicine, Academic Medical Center, Amsterdam, the Netherlands: M. ten Brink and J. Daalhuisen for their technical assistance during the animal experiments, R. de Beer for performing (immuno)histopathological stainings and A. Achouiti and F.E. van den Boogaard for assisting in cytokine measurements.

Footnotes

  • Support Statement

    M. Schouten is supported by a research grant of the Dutch Thrombosis Foundation (grant number TSN 2005–1). J.D. de Boer is supported by a grant from the Netherlands Asthma Foundation (project number 3.2.08.009).

  • Statement of Interest

    None declared.

  • Received January 25, 2012.
  • Accepted July 10, 2012.
  • ©ERS 2013

REFERENCES

  1. ↵
    1. Mandell LA,
    2. Wunderink RG,
    3. Anzueto A,
    4. et al
    . Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27–S72.
    OpenUrlFREE Full Text
  2. ↵
    Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, eds. 12th Edn. Washington DC, public Health Foundation, 2012.
  3. ↵
    1. Balakrishnan I,
    2. Crook P,
    3. Morris R,
    4. et al
    . Early predictors of mortality in pneumococcal bacteraemia. J Infect 2000; 40: 256–261.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Bartlett JG,
    2. Dowell SF,
    3. Mandell LA,
    4. et al
    . Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347–382.
    OpenUrlFREE Full Text
  5. ↵
    1. Conway EM
    . Thrombomodulin and its role in inflammation. Semin Immunopathol 2012; 34: 107–125.
    OpenUrlCrossRefPubMed
    1. Ito T,
    2. Maruyama I
    . Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost 2011; 9: Suppl. 1, 68–73.
    OpenUrl
  6. ↵
    1. Takagi T,
    2. Taguchi O,
    3. Toda M,
    4. et al
    . Inhibition of allergic bronchial asthma by thrombomodulin is mediated by dendritic cells. Am J Respir Crit Care Med 2011; 183: 31–42.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Schouten M,
    2. Wiersinga WJ,
    3. Levi M,
    4. et al
    . Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008; 83: 536–545.
    OpenUrlAbstract/FREE Full Text
    1. Danese S,
    2. Vetrano S,
    3. Zhang L,
    4. et al
    . The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 2010; 115: 1121–1130.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Weiler H
    . Regulation of inflammation by the protein C system. Crit Care Med 2010; 38: Suppl. 2, S18–S25.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Bajzar L,
    2. Manuel R,
    3. Nesheim ME
    . Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477–14484.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Myles T,
    2. Nishimura T,
    3. Yun TH,
    4. et al
    . Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059–51067.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Conway EM,
    2. Van de Wouwer M,
    3. Pollefeyt S,
    4. et al
    . The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor κB and mitogen-activated protein kinase pathways. J Exp Med 2002; 196: 565–577.
    OpenUrlAbstract/FREE Full Text
    1. Geudens N,
    2. Van de Wouwer M,
    3. Vanaudenaerde BM,
    4. et al
    . The lectin-like domain of thrombomodulin protects against ischaemia-reperfusion lung injury. Eur Respir J 2008; 32: 862–870.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Van de Wouwer M,
    2. Plaisance S,
    3. De Vriese A,
    4. et al
    . The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 2006; 4: 1813–1824.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Kawanami O,
    2. Jin E,
    3. Ghazizadeh M,
    4. et al
    . Heterogenous distribution of thrombomodulin and von Willebrand factor in endothelial cells in the human pulmonary microvessels. J Nihon Med Sch 2000; 67: 118–125.
    OpenUrlCrossRef
  14. ↵
    1. Ford VA,
    2. Stringer C,
    3. Kennel SJ
    . Thrombomodulin is preferentially expressed in Balb/c lung microvessels. J Biol Chem 1992; 267: 5446–5450.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Rijneveld AW,
    2. Weijer S,
    3. Florquin S,
    4. et al
    . Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood 2004; 103: 1702–1709.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Schouten M,
    2. van' t Veer C,
    3. Roelofs JJ,
    4. et al
    . Impact of the factor V Leiden mutation on the outcome of pneumococcal pneumonia: a controlled laboratory study. Crit Care 2010; 14: R145.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Rijneveld AW,
    2. Levi M,
    3. Florquin S,
    4. et al
    . Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002; 168: 3507–3511.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Sun K,
    2. Metzger DW
    . Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 2008; 14: 558–564.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Nishimura T,
    2. Myles T,
    3. Piliponsky AM,
    4. et al
    . Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo. Blood 2007; 109: 1992–1997.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Brown JS,
    2. Hussell T,
    3. Gilliland SM,
    4. et al
    . The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice. Proc Natl Acad Sci USA 2002; 99: 16969–16974.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Shi CS,
    2. Shi GY,
    3. Hsiao SM,
    4. et al
    . Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 2008; 112: 3661–3670.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Saito H,
    2. Maruyama I,
    3. Shimazaki S,
    4. et al
    . Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5: 31–41.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
View this article with LENS
Vol 41 Issue 4 Table of Contents
European Respiratory Journal: 41 (4)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The lectin-like domain of thrombomodulin hampers host defence in pneumococcal pneumonia
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
The lectin-like domain of thrombomodulin hampers host defence in pneumococcal pneumonia
Marcel Schouten, J. Daan de Boer, Cornelis van ’t Veer, Joris J.T.H. Roelofs, Joost C.M. Meijers, Marcel Levi, Edward M. Conway, Tom van der Poll
European Respiratory Journal Apr 2013, 41 (4) 935-942; DOI: 10.1183/09031936.00015212

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The lectin-like domain of thrombomodulin hampers host defence in pneumococcal pneumonia
Marcel Schouten, J. Daan de Boer, Cornelis van ’t Veer, Joris J.T.H. Roelofs, Joost C.M. Meijers, Marcel Levi, Edward M. Conway, Tom van der Poll
European Respiratory Journal Apr 2013, 41 (4) 935-942; DOI: 10.1183/09031936.00015212
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Lung biology and experimental studies
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Article

  • Point-of-care lung ultrasound assessment for risk stratification and therapy guiding in COVID-19 patients. A prospective non-interventional study
  • Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients
  • Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease
Show more Original Article

Pulmonary Infections

  • COVID-19 and pneumothorax: multicentre retrospective case series
  • Characteristics and outcomes of asthmatic patients with COVID-19
  • Out-of-ICU noninvasive respiratory support in COVID-19
Show more Pulmonary Infections

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society